首页 > 最新文献

Current Opinion in Endocrinology & Diabetes and Obesity最新文献

英文 中文
Effects of very low carbohydrate ketogenic diets on skeletal health. 极低碳水化合物生酮饮食对骨骼健康的影响。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-08-01 Epub Date: 2023-05-02 DOI: 10.1097/MED.0000000000000811
Cora M Best, Simon Hsu

Purpose of review: Very low carbohydrate ketogenic diet (KD) therapy has been associated with skeletal demineralization in children with drug-resistant epilepsy, but the cause of this association is unclear. Recently, interest in the KD has grown owing to its potential benefits for other illnesses including cancer, type 2 diabetes, obesity, and polycystic kidney disease. Summaries of the best available evidence regarding effects of a KD on skeletal health are lacking.

Recent findings: Recent rodent studies found that a KD can harm the growing skeleton, which corroborates most but not all studies in pediatric patients. Proposed mechanisms include chronic metabolic acidosis and depressed osteoanabolic hormones. Relative to other weight-reducing diets, a weight-reducing KD for treatment of obesity and/or type 2 diabetes in adults has not been associated with adverse skeletal effects. By contrast, recent evidence suggests that adaptation to a eucaloric KD may impair bone remodeling in elite adult athletes. Discrepancies in the literature may relate to differences between study populations and in diet formulation.

Summary: Attention to skeletal health is warranted when using KD therapy given the uncertainty in the literature and suggestive harms in certain populations. Future research should focus on potential mechanisms of injury.

综述目的:极低碳水化合物生酮饮食(KD)疗法与耐药性癫痫患儿骨骼脱钙有关,但这种关联的原因尚不清楚。最近,由于生酮饮食对癌症、2 型糖尿病、肥胖症和多囊肾等其他疾病的潜在益处,人们对生酮饮食的兴趣与日俱增。目前还缺乏有关 KD 对骨骼健康影响的现有最佳证据总结:最近的啮齿类动物研究发现,KD 会损害正在生长的骨骼,这与大多数(但不是所有)针对儿童患者的研究相吻合。提出的机制包括慢性代谢性酸中毒和骨合成代谢激素抑制。与其他减重饮食相比,用于治疗成人肥胖症和/或 2 型糖尿病的减重 KD 并未对骨骼产生不良影响。与此相反,最近的证据表明,适应高热量减重饮食可能会损害成年精英运动员的骨骼重塑。文献中的差异可能与研究人群和饮食配方的不同有关。小结:鉴于文献中的不确定性和某些人群中的提示性危害,在使用 KD 治疗时应关注骨骼健康。未来的研究应关注潜在的损伤机制。
{"title":"Effects of very low carbohydrate ketogenic diets on skeletal health.","authors":"Cora M Best, Simon Hsu","doi":"10.1097/MED.0000000000000811","DOIUrl":"10.1097/MED.0000000000000811","url":null,"abstract":"<p><strong>Purpose of review: </strong>Very low carbohydrate ketogenic diet (KD) therapy has been associated with skeletal demineralization in children with drug-resistant epilepsy, but the cause of this association is unclear. Recently, interest in the KD has grown owing to its potential benefits for other illnesses including cancer, type 2 diabetes, obesity, and polycystic kidney disease. Summaries of the best available evidence regarding effects of a KD on skeletal health are lacking.</p><p><strong>Recent findings: </strong>Recent rodent studies found that a KD can harm the growing skeleton, which corroborates most but not all studies in pediatric patients. Proposed mechanisms include chronic metabolic acidosis and depressed osteoanabolic hormones. Relative to other weight-reducing diets, a weight-reducing KD for treatment of obesity and/or type 2 diabetes in adults has not been associated with adverse skeletal effects. By contrast, recent evidence suggests that adaptation to a eucaloric KD may impair bone remodeling in elite adult athletes. Discrepancies in the literature may relate to differences between study populations and in diet formulation.</p><p><strong>Summary: </strong>Attention to skeletal health is warranted when using KD therapy given the uncertainty in the literature and suggestive harms in certain populations. Future research should focus on potential mechanisms of injury.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 4","pages":"184-191"},"PeriodicalIF":3.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9875415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MR-based techniques for intracortical vessel visualization and characterization: understanding the impact of microvascular disease on skeletal health. 基于磁共振技术的皮质内血管可视化和特征描述:了解微血管疾病对骨骼健康的影响。
IF 2.6 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-08-01 Epub Date: 2023-06-19 DOI: 10.1097/MED.0000000000000819
Maximilian T Löffler, Po-Hung Wu, Galateia J Kazakia

Purpose of review: The relationships between bone vasculature and bone microstructure and strength remain incompletely understood. Addressing this gap will require in vivo imaging capabilities. We describe the relevant vascular anatomy of compact bone, review current magnetic resonance imaging (MRI)-based techniques that allow in vivo assessment of intracortical vasculature, and finally present preliminary studies that apply these techniques to investigate changes in intracortical vessels in aging and disease.

Recent findings: Ultra-short echo time MRI (UTE MRI), dynamic contrast-enhanced MRI (DCE-MRI), and susceptibility-weighted MRI techniques are able to probe intracortical vasculature. Applied to patients with type 2 diabetes, DCE-MRI was able to find significantly larger intracortical vessels compared to nondiabetic controls. Using the same technique, a significantly larger number of smaller vessels was observed in patients with microvascular disease compared to those without. Preliminary data on perfusion MRI showed decreased cortical perfusion with age.

Summary: Development of in vivo techniques for intracortical vessel visualization and characterization will enable the exploration of interactions between the vascular and skeletal systems, and further our understanding of drivers of cortical pore expansion. As we investigate potential pathways of cortical pore expansion, appropriate treatment and prevention strategies will be clarified.

综述的目的:人们对骨血管与骨微结构和强度之间的关系仍不完全了解。要填补这一空白,就必须具备活体成像能力。我们描述了密实骨的相关血管解剖结构,回顾了目前基于磁共振成像(MRI)的可在体内评估皮质内血管的技术,最后介绍了应用这些技术研究皮质内血管在衰老和疾病中变化的初步研究:超短回波时间磁共振成像(UTE MRI)、动态对比增强磁共振成像(DCE-MRI)和感度加权磁共振成像技术能够探测皮层内血管。将 DCE-MRI 应用于 2 型糖尿病患者时,与非糖尿病对照组相比,能发现明显更大的皮质内血管。使用同样的技术,与没有微血管疾病的患者相比,在微血管疾病患者身上观察到的较小血管数量明显增多。灌注核磁共振成像的初步数据显示,随着年龄的增长,皮质灌注减少。总结:开发体内皮质内血管可视化和特征描述技术将有助于探索血管和骨骼系统之间的相互作用,并进一步了解皮质孔扩张的驱动因素。随着我们对皮质孔扩张潜在途径的研究,适当的治疗和预防策略也将得到明确。
{"title":"MR-based techniques for intracortical vessel visualization and characterization: understanding the impact of microvascular disease on skeletal health.","authors":"Maximilian T Löffler, Po-Hung Wu, Galateia J Kazakia","doi":"10.1097/MED.0000000000000819","DOIUrl":"10.1097/MED.0000000000000819","url":null,"abstract":"<p><strong>Purpose of review: </strong>The relationships between bone vasculature and bone microstructure and strength remain incompletely understood. Addressing this gap will require in vivo imaging capabilities. We describe the relevant vascular anatomy of compact bone, review current magnetic resonance imaging (MRI)-based techniques that allow in vivo assessment of intracortical vasculature, and finally present preliminary studies that apply these techniques to investigate changes in intracortical vessels in aging and disease.</p><p><strong>Recent findings: </strong>Ultra-short echo time MRI (UTE MRI), dynamic contrast-enhanced MRI (DCE-MRI), and susceptibility-weighted MRI techniques are able to probe intracortical vasculature. Applied to patients with type 2 diabetes, DCE-MRI was able to find significantly larger intracortical vessels compared to nondiabetic controls. Using the same technique, a significantly larger number of smaller vessels was observed in patients with microvascular disease compared to those without. Preliminary data on perfusion MRI showed decreased cortical perfusion with age.</p><p><strong>Summary: </strong>Development of in vivo techniques for intracortical vessel visualization and characterization will enable the exploration of interactions between the vascular and skeletal systems, and further our understanding of drivers of cortical pore expansion. As we investigate potential pathways of cortical pore expansion, appropriate treatment and prevention strategies will be clarified.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 4","pages":"192-199"},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10313191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skeletal health in diabetes. 糖尿病患者的骨骼健康
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-08-01 DOI: 10.1097/MED.0000000000000820
Viral N Shah
{"title":"Skeletal health in diabetes.","authors":"Viral N Shah","doi":"10.1097/MED.0000000000000820","DOIUrl":"10.1097/MED.0000000000000820","url":null,"abstract":"","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 4","pages":"181-183"},"PeriodicalIF":3.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of incretins on skeletal health. 胰蛋白酶对骨骼健康的影响
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-08-01 Epub Date: 2023-06-12 DOI: 10.1097/MED.0000000000000813
Jakob Starup-Linde, Katrine Hygum, Bente Langdahl

Purpose of review: The incretin hormones, glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have been shown to decrease bone resorption in humans. The aim of this review is to collate evidence and current advances in the research within the last year on the effect of incretins on skeletal health.

Recent findings: Preclinical studies show potential direct beneficial effects on bone by GLP-1 and GIP, however real world epidemiological data show no effects of GLP-1 receptor analogues on fracture risk. This may be due to the weight loss accompanied by GLP-1 treatment which may have detrimental effects on bone. GIP is shown to reduce bone resorption and increase bone formation. Further evidence suggests an additive effect of GIP and glucagon like peptide-2, which could affect bone by different mechanisms.

Summary: GIP and GLP-1 based therapies are more widespread used and may have potential beneficial effects on bone, possibly counterbalanced by weight loss. Long-term effects and side-effects of GIP or GIP/ GLP-2 co-administration remain to be elucidated, and longer term treatment trials are needed.

综述的目的:增量素激素、胰高血糖素样肽-1(GLP-1)和胃抑制肽(GIP)已被证明可减少人体骨吸收。本综述旨在整理去年有关胰高血糖素对骨骼健康影响的证据和最新研究进展:临床前研究显示,GLP-1 和 GIP 对骨骼有潜在的直接益处,但现实世界的流行病学数据显示,GLP-1 受体类似物对骨折风险没有影响。这可能是因为 GLP-1 治疗会导致体重减轻,而体重减轻可能会对骨骼产生不利影响。GIP 可减少骨吸收,增加骨形成。更多证据表明,GIP 和胰高血糖素样肽-2 具有叠加效应,可通过不同机制影响骨骼。小结:基于 GIP 和 GLP-1 的疗法得到了更广泛的应用,可能会对骨骼产生潜在的有益影响,但可能会被体重减轻所抵消。GIP 或 GIP/ GLP-2 联合用药的长期效果和副作用仍有待阐明,需要进行更长期的治疗试验。
{"title":"Effect of incretins on skeletal health.","authors":"Jakob Starup-Linde, Katrine Hygum, Bente Langdahl","doi":"10.1097/MED.0000000000000813","DOIUrl":"10.1097/MED.0000000000000813","url":null,"abstract":"<p><strong>Purpose of review: </strong>The incretin hormones, glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have been shown to decrease bone resorption in humans. The aim of this review is to collate evidence and current advances in the research within the last year on the effect of incretins on skeletal health.</p><p><strong>Recent findings: </strong>Preclinical studies show potential direct beneficial effects on bone by GLP-1 and GIP, however real world epidemiological data show no effects of GLP-1 receptor analogues on fracture risk. This may be due to the weight loss accompanied by GLP-1 treatment which may have detrimental effects on bone. GIP is shown to reduce bone resorption and increase bone formation. Further evidence suggests an additive effect of GIP and glucagon like peptide-2, which could affect bone by different mechanisms.</p><p><strong>Summary: </strong>GIP and GLP-1 based therapies are more widespread used and may have potential beneficial effects on bone, possibly counterbalanced by weight loss. Long-term effects and side-effects of GIP or GIP/ GLP-2 co-administration remain to be elucidated, and longer term treatment trials are needed.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 4","pages":"206-212"},"PeriodicalIF":3.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic strategies in adrenal insufficiency. 肾上腺功能不全的诊断策略。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.1097/MED.0000000000000806
Vasiliki Siampanopoulou, Elisavet Tasouli, Anna Angelousi

Purpose of review: Adrenal insufficiency (AI) is the clinical manifestation of deficient production of glucocorticoids with occasionally deficiency also in mineralocorticoids and adrenal androgens and constitutes a fatal disorder if left untreated. The aim of this review is to summarize the new trends in diagnostic methods used for determining the presence of AI.

Recent findings: Novel aetiologies of AI have emerged; severe acute respiratory syndrome coronavirus 2 infection was linked to increased frequency of primary AI (PAI). A new class of drugs, the immune checkpoint inhibitors (ICIs) widely used for the treatment of several malignancies, has been implicated mostly with secondary AI, but also with PAI. Salivary cortisol is considered a noninvasive and patient-friendly tool and has shown promising results in diagnosing AI, although the normal cut-off values remain an issue of debate depending on the technique used. Liquid chromatography-mass spectrometry (LC-MS/MS) is the most reliable technique although not widely available.

Summary: Our research has shown that little progress has been made regarding our knowledge on AI. Coronavirus disease 2019 and ICIs use constitute new evidence on the pathogenesis of AI. The short synacthen test (SST) remains the 'gold-standard' method for confirmation of AI diagnosis, although salivary cortisol is a promising tool.

综述目的:肾上腺功能不全(AI)是糖皮质激素分泌不足的临床表现,偶尔也会缺乏矿化皮质激素和肾上腺雄激素,如果不及时治疗,会构成致命的疾病。本综述的目的是总结用于确定人工智能存在的诊断方法的新趋势。最新发现:人工智能的新病因学已经出现;严重急性呼吸综合征冠状病毒2感染与原发性人工智能(PAI)的频率增加有关。一类新的药物,免疫检查点抑制剂(ICIs)广泛用于治疗几种恶性肿瘤,主要与继发性AI有关,但也与PAI有关。唾液皮质醇被认为是一种无创且对患者友好的工具,在诊断人工智能方面显示出有希望的结果,尽管根据所使用的技术,正常的临界值仍然是一个有争议的问题。液相色谱-质谱(LC-MS/MS)是最可靠的技术,但尚未广泛使用。总结:我们的研究表明,我们在人工智能方面的知识几乎没有进步。2019冠状病毒病和ICIs的使用为AI的发病机制提供了新的证据。短突触测试(SST)仍然是人工智能诊断的“金标准”方法,尽管唾液皮质醇是一种很有前途的工具。
{"title":"Diagnostic strategies in adrenal insufficiency.","authors":"Vasiliki Siampanopoulou,&nbsp;Elisavet Tasouli,&nbsp;Anna Angelousi","doi":"10.1097/MED.0000000000000806","DOIUrl":"https://doi.org/10.1097/MED.0000000000000806","url":null,"abstract":"<p><strong>Purpose of review: </strong>Adrenal insufficiency (AI) is the clinical manifestation of deficient production of glucocorticoids with occasionally deficiency also in mineralocorticoids and adrenal androgens and constitutes a fatal disorder if left untreated. The aim of this review is to summarize the new trends in diagnostic methods used for determining the presence of AI.</p><p><strong>Recent findings: </strong>Novel aetiologies of AI have emerged; severe acute respiratory syndrome coronavirus 2 infection was linked to increased frequency of primary AI (PAI). A new class of drugs, the immune checkpoint inhibitors (ICIs) widely used for the treatment of several malignancies, has been implicated mostly with secondary AI, but also with PAI. Salivary cortisol is considered a noninvasive and patient-friendly tool and has shown promising results in diagnosing AI, although the normal cut-off values remain an issue of debate depending on the technique used. Liquid chromatography-mass spectrometry (LC-MS/MS) is the most reliable technique although not widely available.</p><p><strong>Summary: </strong>Our research has shown that little progress has been made regarding our knowledge on AI. Coronavirus disease 2019 and ICIs use constitute new evidence on the pathogenesis of AI. The short synacthen test (SST) remains the 'gold-standard' method for confirmation of AI diagnosis, although salivary cortisol is a promising tool.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 3","pages":"141-153"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10312617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers in gastroenteropancreatic neuroendocrine neoplasms. 胃肠胰神经内分泌肿瘤的生物标志物研究。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.1097/MED.0000000000000805
Isa Mulingbayan Jacoba, H Christian Weber

Purpose of review: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) represent a heterogenous group of rare tumors emanating from neuroendocrine cells that are clinically silent for prolonged periods of time without detection. Traditional biomarkers lack sufficiently high enough specificity and sensitivity for these tumors and their secreted products. New molecules are sought to improve accuracy of detection and monitoring of GEP-NENs. The purpose of this review is to highlight recent advances in the discovery of novel biomarkers and their potential characteristics and utility as markers of GEP-NENs.

Recent findings: Several recent GEP-NEN investigations regarding NETest demonstrate superior sensitivity and specificity in diagnosis and disease monitoring as compared with chromogranin A. Among several tissue-based emergent candidate molecules as biomarkers for GEP-NEN INSM1 has demonstrated consistently excellent characteristics when compared with traditional markers including chromogranin A, synaptophysin, and CD56.

Summary: For the diagnosis and clinical monitoring of NEN, there still exists a considerable need for better biomarkers. Novel technology has resulted in a promising liquid biopsy for the detection and monitoring of GEP-NENs. The search for improved tissue biomarkers has resulted in identification of one potential candidate whereas several others remain in the investigatory phase.

综述目的:胃肠胰神经内分泌肿瘤(GEP-NEN)是一种异质性的罕见肿瘤,起源于神经内分泌细胞,临床表现为长时间无症状而未被发现。传统的生物标志物对这些肿瘤及其分泌产物缺乏足够高的特异性和敏感性。为了提高GEP-NENs检测和监测的准确性,研究人员正在寻求新的分子。本文综述了近年来新型生物标记物的发现及其作为GEP-NENs标记物的潜在特征和用途。最近的发现:最近几项关于neest的GEP-NEN研究表明,与嗜铬粒蛋白A相比,neest在诊断和疾病监测方面具有优越的敏感性和特异性。在几种基于组织的新兴候选分子中,INSM1作为GEP-NEN的生物标志物,与嗜铬粒蛋白A、synaptophysin和CD56等传统标志物相比,一直表现出优异的特征。摘要:对于NEN的诊断和临床监测,仍然需要更好的生物标志物。新技术导致了一种有前途的液体活检检测和监测GEP-NENs。对改进的组织生物标志物的研究已经确定了一种潜在的候选物,而其他一些仍处于研究阶段。
{"title":"Biomarkers in gastroenteropancreatic neuroendocrine neoplasms.","authors":"Isa Mulingbayan Jacoba,&nbsp;H Christian Weber","doi":"10.1097/MED.0000000000000805","DOIUrl":"https://doi.org/10.1097/MED.0000000000000805","url":null,"abstract":"<p><strong>Purpose of review: </strong>Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) represent a heterogenous group of rare tumors emanating from neuroendocrine cells that are clinically silent for prolonged periods of time without detection. Traditional biomarkers lack sufficiently high enough specificity and sensitivity for these tumors and their secreted products. New molecules are sought to improve accuracy of detection and monitoring of GEP-NENs. The purpose of this review is to highlight recent advances in the discovery of novel biomarkers and their potential characteristics and utility as markers of GEP-NENs.</p><p><strong>Recent findings: </strong>Several recent GEP-NEN investigations regarding NETest demonstrate superior sensitivity and specificity in diagnosis and disease monitoring as compared with chromogranin A. Among several tissue-based emergent candidate molecules as biomarkers for GEP-NEN INSM1 has demonstrated consistently excellent characteristics when compared with traditional markers including chromogranin A, synaptophysin, and CD56.</p><p><strong>Summary: </strong>For the diagnosis and clinical monitoring of NEN, there still exists a considerable need for better biomarkers. Novel technology has resulted in a promising liquid biopsy for the detection and monitoring of GEP-NENs. The search for improved tissue biomarkers has resulted in identification of one potential candidate whereas several others remain in the investigatory phase.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 3","pages":"175-180"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular tools for diagnosing diseases of the adrenal cortex. 诊断肾上腺皮质疾病的分子工具。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.1097/MED.0000000000000809
Fabio R Faucz, Andrea G Maria, Constantine A Stratakis

Purpose of review: The adrenal glands produce some of the most essential for life hormones, including cortisol and other steroids, and catecholamines. The former is produced from the adrenal cortex, whereas the latter is from the medulla. The two parts are anatomically and functionally distinct and it would be impossible in the context of one short article to cover all molecular updates on both the cortex and the medulla. Thus, in this review, we focus on the molecular tools available for diagnosing adrenocortical diseases, such as adrenal insufficiency, Cushing and Conn syndromes, and their potential for advancing medical care and clinical outcome.

Recent findings: The advent of next generation sequencing opened doors for finding genetic diseases and signaling pathways involved in adrenocortical diseases. In addition, the combination of molecular data and clinicopathologic assessment might be the best approach for an early and precise diagnosis contributing to therapeutic decisions and improvement of patient outcomes.

Summary: Diagnosing adrenocortical diseases can be challenging; however, the progress of molecular tools for adrenocortical disease diagnosis has greatly contributed to early detection and to meliorate patient outcomes.

综述目的:肾上腺产生一些最重要的生命激素,包括皮质醇和其他类固醇,以及儿茶酚胺。前者由肾上腺皮质产生,而后者由髓质产生。这两个部分在解剖学和功能上是不同的,在一篇短文的背景下,不可能涵盖皮层和髓质的所有分子更新。因此,在这篇综述中,我们将重点关注可用于诊断肾上腺皮质疾病的分子工具,如肾上腺功能不全、库欣综合征和康氏综合征,以及它们在促进医疗保健和临床结果方面的潜力。最新发现:下一代测序的出现为发现与肾上腺皮质疾病有关的遗传疾病和信号通路打开了大门。此外,结合分子数据和临床病理评估可能是早期和精确诊断的最佳方法,有助于治疗决策和改善患者预后。总结:肾上腺皮质疾病的诊断具有挑战性;然而,分子工具在肾上腺皮质疾病诊断方面的进展极大地促进了早期发现和改善患者的预后。
{"title":"Molecular tools for diagnosing diseases of the adrenal cortex.","authors":"Fabio R Faucz,&nbsp;Andrea G Maria,&nbsp;Constantine A Stratakis","doi":"10.1097/MED.0000000000000809","DOIUrl":"https://doi.org/10.1097/MED.0000000000000809","url":null,"abstract":"<p><strong>Purpose of review: </strong>The adrenal glands produce some of the most essential for life hormones, including cortisol and other steroids, and catecholamines. The former is produced from the adrenal cortex, whereas the latter is from the medulla. The two parts are anatomically and functionally distinct and it would be impossible in the context of one short article to cover all molecular updates on both the cortex and the medulla. Thus, in this review, we focus on the molecular tools available for diagnosing adrenocortical diseases, such as adrenal insufficiency, Cushing and Conn syndromes, and their potential for advancing medical care and clinical outcome.</p><p><strong>Recent findings: </strong>The advent of next generation sequencing opened doors for finding genetic diseases and signaling pathways involved in adrenocortical diseases. In addition, the combination of molecular data and clinicopathologic assessment might be the best approach for an early and precise diagnosis contributing to therapeutic decisions and improvement of patient outcomes.</p><p><strong>Summary: </strong>Diagnosing adrenocortical diseases can be challenging; however, the progress of molecular tools for adrenocortical disease diagnosis has greatly contributed to early detection and to meliorate patient outcomes.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 3","pages":"154-160"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10256823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.1097/MED.0000000000000808
{"title":"Editorial introductions.","authors":"","doi":"10.1097/MED.0000000000000808","DOIUrl":"https://doi.org/10.1097/MED.0000000000000808","url":null,"abstract":"","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 3","pages":"v"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10628044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucocorticoid withdrawal syndrome: what to expect and how to manage. 糖皮质激素戒断综合征:预期和如何管理。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.1097/MED.0000000000000804
Verena Theiler-Schwetz, Alessandro Prete

Purpose of review: Glucocorticoid withdrawal syndrome (GWS) can develop after withdrawing exposure to supraphysiological levels of endogenous or exogenous glucocorticoids due to an established physical dependence. It is characterised by symptoms similar to adrenal insufficiency but needs to be regarded as a separate entity. GWS is often under-recognised in clinical practice and affected patients can experience significant impairment in their quality of life.

Recent findings: A cornerstone in GWS management is adequate patient education and reassurance that symptoms are expected and typically temporary. Patients with endogenous Cushing's syndrome need to be aware that psychopathology may persist into the postoperative period. GWS is more likely to develop in severe Cushing's syndrome and in patients with very low levels of cortisol after surgery. Postoperatively, glucocorticoid replacement should be initiated and tapered in an individualised approach but there is currently no consensus on the best tapering strategy. If symptoms of GWS develop, glucocorticoid replacement ought to be temporarily increased to the previous, well tolerated dose. No randomised studies have thus far compared regimens for withdrawing glucocorticoids after treatment for anti-inflammatory or immunosuppressive causes to determine the best and safest tapering strategy. One open-label, single-arm trial in patients with asthma has recently proposed a personalised glucocorticoid tapering regimen which included the systematic assessment of adrenal function.

Summary: Awareness of GWS by treating physicians and patient education are essential. Evidence on optimal GWS management after Cushing's syndrome treatment is scarce, but new data are emerging for tapering after long-term glucocorticoid treatment.

综述目的:糖皮质激素戒断综合征(GWS)可在因身体依赖而戒断暴露于超生理水平的内源性或外源性糖皮质激素后发生。它的特点是症状类似于肾上腺功能不全,但需要被视为一个单独的实体。GWS在临床实践中往往未得到充分认识,受影响的患者可能会经历生活质量的严重损害。最新发现:GWS管理的基石是充分的患者教育和保证症状是预期的,通常是暂时的。内源性库欣综合征患者需要意识到,精神病理可能持续到术后。GWS更可能发生在严重的库欣综合征和手术后皮质醇水平很低的患者中。术后,糖皮质激素替代应开始并逐渐减少个体化的方法,但目前没有共识的最佳逐渐减少的策略。如果出现GWS症状,应暂时增加糖皮质激素替代剂量至先前耐受良好的剂量。到目前为止,还没有随机研究比较抗炎或免疫抑制治疗后停用糖皮质激素的方案,以确定最佳和最安全的减量策略。一项针对哮喘患者的开放标签单臂试验最近提出了个体化糖皮质激素减量方案,其中包括对肾上腺功能的系统评估。总结:治疗医师和患者教育对GWS的认识至关重要。关于库欣综合征治疗后最佳GWS管理的证据很少,但长期糖皮质激素治疗后逐渐减少的新数据正在出现。
{"title":"Glucocorticoid withdrawal syndrome: what to expect and how to manage.","authors":"Verena Theiler-Schwetz,&nbsp;Alessandro Prete","doi":"10.1097/MED.0000000000000804","DOIUrl":"https://doi.org/10.1097/MED.0000000000000804","url":null,"abstract":"<p><strong>Purpose of review: </strong>Glucocorticoid withdrawal syndrome (GWS) can develop after withdrawing exposure to supraphysiological levels of endogenous or exogenous glucocorticoids due to an established physical dependence. It is characterised by symptoms similar to adrenal insufficiency but needs to be regarded as a separate entity. GWS is often under-recognised in clinical practice and affected patients can experience significant impairment in their quality of life.</p><p><strong>Recent findings: </strong>A cornerstone in GWS management is adequate patient education and reassurance that symptoms are expected and typically temporary. Patients with endogenous Cushing's syndrome need to be aware that psychopathology may persist into the postoperative period. GWS is more likely to develop in severe Cushing's syndrome and in patients with very low levels of cortisol after surgery. Postoperatively, glucocorticoid replacement should be initiated and tapered in an individualised approach but there is currently no consensus on the best tapering strategy. If symptoms of GWS develop, glucocorticoid replacement ought to be temporarily increased to the previous, well tolerated dose. No randomised studies have thus far compared regimens for withdrawing glucocorticoids after treatment for anti-inflammatory or immunosuppressive causes to determine the best and safest tapering strategy. One open-label, single-arm trial in patients with asthma has recently proposed a personalised glucocorticoid tapering regimen which included the systematic assessment of adrenal function.</p><p><strong>Summary: </strong>Awareness of GWS by treating physicians and patient education are essential. Evidence on optimal GWS management after Cushing's syndrome treatment is scarce, but new data are emerging for tapering after long-term glucocorticoid treatment.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 3","pages":"167-174"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10604738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Surgical approaches to the adrenal gland. 肾上腺的外科手术。
IF 3.2 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-06-01 DOI: 10.1097/MED.0000000000000810
Alaa Sada, Travis J McKenzie

Purpose of review: Review the literature on the surgical management of adrenal diseases, highlighting the various surgical approaches and their respective pros and cons.

Recent findings: Minimally invasive adrenalectomy is commonly used for small and benign adrenal tumors, whereas open adrenalectomy is preferred for larger tumors and primary adrenal malignancy. Although minimally invasive adrenalectomy results in shorter recovery and fewer complications compared with open, the latter offers better oncologic outcomes in the setting of primary adrenal malignancy. Adrenalectomy is performed transabdominally or retroperitoneoscopically, both yielding equivalent results and recovery. Traditional laparoscopic or robotic equipment can be utilized for either minimally invasive approach. Subtotal adrenalectomy may be appropriate for patients with genetically associated pheochromocytoma to preserve cortical function and reduce the risk of adrenal insufficiency. However, the potential benefits of sparing adrenal function must be weighed against the risk of recurrence.

Summary: Adrenalectomy is becoming increasingly common worldwide. For benign and small adrenal tumors, minimally invasive adrenalectomy is generally considered the standard approach, while open adrenalectomy is preferred for primary adrenal malignancy and larger tumors. Subtotal adrenalectomy may be appropriate for patients with bilateral adrenal pheochromocytoma, as it can reduce the need for lifelong glucocorticoid dependency.

综述目的:回顾关于肾上腺疾病的外科治疗的文献,强调各种手术方法及其优缺点。最近的研究发现:微创肾上腺切除术常用于小的和良性的肾上腺肿瘤,而对于较大的肿瘤和原发性肾上腺恶性肿瘤则首选开放肾上腺切除术。虽然微创肾上腺切除术的恢复时间较短,并发症较少,但后者在原发性肾上腺恶性肿瘤中提供了更好的肿瘤预后。经腹或经腹膜后腹腔镜行肾上腺切除术,均可获得相同的结果和恢复。传统的腹腔镜或机器人设备可用于微创方法。肾上腺次全切除术可能适合遗传性嗜铬细胞瘤患者,以保持皮质功能并降低肾上腺功能不全的风险。然而,保留肾上腺功能的潜在益处必须与复发风险进行权衡。摘要:肾上腺切除术在世界范围内越来越普遍。对于良性和小型肾上腺肿瘤,一般认为微创肾上腺切除术是标准的治疗方法,而对于原发性肾上腺恶性肿瘤和较大的肿瘤,首选开放性肾上腺切除术。肾上腺次全切除术可能适合双侧肾上腺嗜铬细胞瘤患者,因为它可以减少终身糖皮质激素依赖的需要。
{"title":"Surgical approaches to the adrenal gland.","authors":"Alaa Sada,&nbsp;Travis J McKenzie","doi":"10.1097/MED.0000000000000810","DOIUrl":"https://doi.org/10.1097/MED.0000000000000810","url":null,"abstract":"<p><strong>Purpose of review: </strong>Review the literature on the surgical management of adrenal diseases, highlighting the various surgical approaches and their respective pros and cons.</p><p><strong>Recent findings: </strong>Minimally invasive adrenalectomy is commonly used for small and benign adrenal tumors, whereas open adrenalectomy is preferred for larger tumors and primary adrenal malignancy. Although minimally invasive adrenalectomy results in shorter recovery and fewer complications compared with open, the latter offers better oncologic outcomes in the setting of primary adrenal malignancy. Adrenalectomy is performed transabdominally or retroperitoneoscopically, both yielding equivalent results and recovery. Traditional laparoscopic or robotic equipment can be utilized for either minimally invasive approach. Subtotal adrenalectomy may be appropriate for patients with genetically associated pheochromocytoma to preserve cortical function and reduce the risk of adrenal insufficiency. However, the potential benefits of sparing adrenal function must be weighed against the risk of recurrence.</p><p><strong>Summary: </strong>Adrenalectomy is becoming increasingly common worldwide. For benign and small adrenal tumors, minimally invasive adrenalectomy is generally considered the standard approach, while open adrenalectomy is preferred for primary adrenal malignancy and larger tumors. Subtotal adrenalectomy may be appropriate for patients with bilateral adrenal pheochromocytoma, as it can reduce the need for lifelong glucocorticoid dependency.</p>","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":"30 3","pages":"161-166"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10255878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Current Opinion in Endocrinology & Diabetes and Obesity
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1